SE364311B - - Google Patents

Info

Publication number
SE364311B
SE364311B SE13924/69A SE1392469A SE364311B SE 364311 B SE364311 B SE 364311B SE 13924/69 A SE13924/69 A SE 13924/69A SE 1392469 A SE1392469 A SE 1392469A SE 364311 B SE364311 B SE 364311B
Authority
SE
Sweden
Application number
SE13924/69A
Inventor
J Antoine
Original Assignee
Siderurgie Fse Inst Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siderurgie Fse Inst Rech filed Critical Siderurgie Fse Inst Rech
Publication of SE364311B publication Critical patent/SE364311B/xx

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D11/00—Arrangement of elements for electric heating in or on furnaces
    • F27D11/08—Heating by electric discharge, e.g. arc discharge
    • C—CHEMISTRY; METALLURGY
    • C21—METALLURGY OF IRON
    • C21C—PROCESSING OF PIG-IRON, e.g. REFINING, MANUFACTURE OF WROUGHT-IRON OR STEEL; TREATMENT IN MOLTEN STATE OF FERROUS ALLOYS
    • C21C5/00—Manufacture of carbon-steel, e.g. plain mild steel, medium carbon steel or cast steel or stainless steel
    • C21C5/52—Manufacture of steel in electric furnaces
    • C21C5/5252—Manufacture of steel in electric furnaces in an electrically heated multi-chamber furnace, a combination of electric furnaces or an electric furnace arranged for associated working with a non electric furnace
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D11/00—Arrangement of elements for electric heating in or on furnaces
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F27—FURNACES; KILNS; OVENS; RETORTS
    • F27D—DETAILS OR ACCESSORIES OF FURNACES, KILNS, OVENS, OR RETORTS, IN SO FAR AS THEY ARE OF KINDS OCCURRING IN MORE THAN ONE KIND OF FURNACE
    • F27D3/00—Charging; Discharging; Manipulation of charge
    • F27D3/18—Charging particulate material using a fluid carrier

Landscapes

  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Organic Chemistry (AREA)
  • Vertical, Hearth, Or Arc Furnaces (AREA)
  • Furnace Details (AREA)
  • Discharge Heating (AREA)
SE13924/69A 1968-10-17 1969-10-10 SE364311B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR170197 1968-10-17

Publications (1)

Publication Number Publication Date
SE364311B true SE364311B (de) 1974-02-18

Family

ID=8655735

Family Applications (1)

Application Number Title Priority Date Filing Date
SE13924/69A SE364311B (de) 1968-10-17 1969-10-10

Country Status (10)

Country Link
US (1) US3610795A (de)
JP (1) JPS4829422B1 (de)
BE (1) BE739974A (de)
BR (1) BR6913348D0 (de)
DE (1) DE1952407B2 (de)
ES (1) ES372628A1 (de)
FR (1) FR1601438A (de)
GB (1) GB1252310A (de)
LU (1) LU59646A1 (de)
SE (1) SE364311B (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891427A (en) * 1972-10-12 1975-06-24 Lectromelt Corp Method for melting prereduced ore and scrap
SE378735B (de) * 1972-11-17 1975-09-08 Asea Ab
FR2220584B1 (de) * 1973-03-05 1976-05-21 Siderurgie Fse Inst Rech
US3939297A (en) * 1973-12-07 1976-02-17 Chase Brass & Copper Co., Incorporated Stoker feed system
SE7503782L (sv) * 1975-04-02 1976-10-03 Asea Ab Sett och anordning for smeltreduktion av finkornigt jernoxidhaltigt material
DE2632707C3 (de) * 1976-07-21 1983-04-07 Ernst Dipl.-Ing. 4006 Erkrath Beiersdorf Beschickungsanlage an Elektro-Lichtbogenöfen zur Zugabe von Legierungsmitteln und Zuschlagstoffen
US4133967A (en) * 1977-06-24 1979-01-09 The United States Of America As Represented By The Secretary Of The Interior Two-stage electric arc - electroslag process and apparatus for continuous steelmaking
US4447906A (en) * 1981-02-02 1984-05-08 Lectromelt Corporation Arc furnace for producing aluminum
SE8303372L (sv) * 1983-06-14 1984-12-15 Asea Ab Ugnsanordning for smeltning av metaller eller metallegeringar
AT384669B (de) * 1986-03-17 1987-12-28 Voest Alpine Ag Anlage zur herstellung von stahl aus schrott
CA1311787C (en) * 1986-06-24 1992-12-22 Masahisa Tate Method of bottom blowing operation of a steel making electric furnace
FR2705767B1 (fr) * 1993-05-27 1995-07-21 Lorraine Laminage Procédé et installation de production d'acier liquide à partir de matières ferreuses riches en matières carbonées.
DE4339226A1 (de) * 1993-11-15 1995-05-18 Mannesmann Ag Verfahren und Vorrichtung zur Wertstoffgewinnung
AT404841B (de) * 1995-04-10 1999-03-25 Voest Alpine Ind Anlagen Anlage und verfahren zum herstellen von eisenschmelzen
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
AU5273700A (en) * 1999-05-18 2000-12-05 Danieli Technology, Inc. Electric arc furnace for continuous charging
EP1702983A3 (de) 2000-04-13 2007-01-10 Medical University of South Carolina Gewebespezifische und pathogenspezifische giftige Verbindungen, Ribozyme, DNAzyme und Antisenseolinukleotide sowie Anwendungen dafür
US20040067991A1 (en) * 2000-07-06 2004-04-08 Greig Nigel H Tetrahydrobenzothiazole analogues as neuroprotective agents
US6642002B2 (en) 2000-07-17 2003-11-04 Vanderbilt University Method of diagnosing pulmonary hypertension
WO2002030465A2 (en) 2000-10-12 2002-04-18 University Of Rochester Compositions that inhibit proliferation of cancer cells
WO2002081710A1 (en) * 2001-04-06 2002-10-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Artificial chromosomes that can shuttle between bacteria, yeast, and mammalian cells
JP2005504829A (ja) * 2001-10-01 2005-02-17 バンダービルト ユニバーシティ 構造的心疾患における心筋機能不全を処置するためのカルモジュリンキナーゼｉｉインヒビターの使用
US20040248289A1 (en) * 2001-10-04 2004-12-09 Vladimir Noskov Tandem repeat markers
ATE469167T1 (de) 2002-02-06 2010-06-15 Vicor Technologies Inc Anti-infarkt-moleküle
CA2489540A1 (en) 2002-06-14 2003-12-31 The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Office Of Technology Transfer Methods of treating and preventing colitis involving il-13 and nk-t cells
CA2495478A1 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
AU2003298650B2 (en) 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
WO2004047749A2 (en) 2002-11-21 2004-06-10 University Of Utah Research Foundation Purinergic modulation of smell
EP1711517A4 (de) 2004-01-21 2008-02-13 Univ Utah Res Found MUTANTER NATRIUMKANAL NAv1.7 UND DAMIT VERBUNDENE VERFAHREN
WO2005086800A2 (en) 2004-03-04 2005-09-22 Vanderbilt University Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling
EP1734821A4 (de) * 2004-04-14 2011-07-06 Uab Research Foundation Aktivatoren der hexosaminbiosynthese als hemmer für durch ischämieschock oder hämorrhagischen schock induzierte schäden
US20050244335A1 (en) * 2004-05-03 2005-11-03 Rinehart John J Methods and compositions related to increasing antitumor activity of chemotherapeutic agents
US20080269116A1 (en) 2004-05-11 2008-10-30 Taub Dennis D Methods of Inhibiting Proinflammatory Cytokine Expression Using Ghrelin
EP3225633B1 (de) 2004-05-21 2020-03-25 The UAB Research Foundation Variable lymphozytenrezeptoren, verwandte polypeptide und nukleinsäuren sowie verwendung dafür
EP1811839A4 (de) * 2004-11-18 2008-08-06 Univ Rochester Verfahren und zusammensetzungen in verbindung mit esculentosid a
CA2593979C (en) 2004-12-21 2018-09-18 Musc Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
ES2412005T3 (es) 2005-04-15 2013-07-09 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Services Tratamiento y prevención de la enfermedad intestinal inflamatoria que implica IL-13 y células NKT
AU2005332058B2 (en) 2005-05-19 2011-12-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Functional epitopes of Streptococcus pneumoniae PsaA antigen and uses thereof
US8859585B2 (en) 2005-05-25 2014-10-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Scopolamine for the treatment of depression and anxiety
AU2006325040B2 (en) 2005-06-07 2012-04-19 Dsm Nutritional Products Ag Eukaryotic microorganisms for producing lipids and antioxidants
CA2625891A1 (en) 2005-10-14 2007-04-26 Carlton D. Donald Inhibition of pax2 by defb1 induction as a therapy for cancer
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP3088522B1 (de) 2005-12-29 2017-11-29 The Regents of the University of California Verfahren und zusammensetzungen in verbindung mit mutanter kunitz-domäne i von tfpi-2
EP2913056A1 (de) 2006-01-05 2015-09-02 The University of Utah Research Foundation Verfahren und Zusammensetzungen in Zusammenhang mit der Verbesserung von Eigenschaften pharmakologischer Wirkstoffe für das Nervensystem
CA2638911C (en) 2006-02-06 2018-01-23 Burnham Institute For Medical Research Methods and compositions related to targeting tumors and wounds
EP1998792B1 (de) * 2006-03-01 2015-02-18 The University of Utah Research Foundation Verfahren und zusammensetzungen in verbindung mit der synthese zyklischer peptide
US8470965B2 (en) * 2006-03-01 2013-06-25 University Of Utah Research Foundation Methods and compositions related to cyclic peptide synthesis
CA2644338A1 (en) 2006-03-02 2007-09-07 The Uab Research Foundation Mycobacterial disease detection, treatment, and drug discovery
EP2043642B1 (de) 2006-07-10 2015-03-25 Synapsin Pharmaceuticals, Inc. Zusammensetzungen und verfahren in zusammenhang mit solenopsinen und ihre verwendung zur behandlung neurologischer erkrankungen und erhöhung der körperlichen leistung
DK2049564T3 (en) 2006-08-02 2017-07-24 Uab Res Found METHODS AND COMPOSITIONS RELATED TO SOLUBLE MONOCLONAL VARIABLE Lymphocyte RECEPTORS WITH DEFINED ANTIGEN SPECIFICITY
EP2066812A4 (de) 2006-09-21 2010-04-28 Univ Rochester Zusammensetzungen und verfahren in zusammenhang mit proteinverschiebungstherapie für myotone dystrophie
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
KR20090089462A (ko) 2006-12-11 2009-08-21 유니버시티 오브 유타 리써치 파운데이션 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
EP2101567A4 (de) 2007-01-18 2010-04-21 Univ Utah Res Found Zusammensetzungen und verfahren zur erkennung, behandlung oder prävention von reduktivem stress
EP2596799B1 (de) 2007-02-08 2016-11-23 University of Utah Research Foundation Verfahren und Zusammensetzungen zur Viruseindringungshemmung
CA2681634A1 (en) 2007-03-22 2008-09-25 Yale University Methods and compositions related to riboswitches that control alternative splicing
EP2433496A1 (de) 2007-05-08 2012-03-28 Burnham Institute for Medical Research Nicht gewebespezifische Alkali-Phosphat-Hemmer und deren Verwendung zur Behandlung von Gefäßverkalkungen
CA2687024A1 (en) 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
EP2164957B1 (de) 2007-05-23 2017-07-12 The UAB Research Foundation Enttoxifizierte neuraminidase aus pneumococcus und ihre verwendungen
EP2426219A1 (de) 2007-05-29 2012-03-07 Yale University Riboswitches sowie Verfahren und Zusammensetzungen zur Verwendung von und mit Riboswitches
DK2166845T3 (en) 2007-06-21 2016-02-01 Musc Found For Res Dev ALFA-connexin C-terminal (ACT) peptides FOR THE TREATMENT OF AGE-related macular degeneration
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
WO2009021163A2 (en) * 2007-08-08 2009-02-12 University Of Rochester Enhancing gene transfer
US20090053192A1 (en) * 2007-08-10 2009-02-26 Burnham Institute For Medical Research Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
US8501912B2 (en) 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
EP2853897A1 (de) 2008-05-08 2015-04-01 University Of Utah Research Foundation Sensorische Rezeptoren für chronische Müdigkeit und Schmerzen und Verwendungen davon
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
US8816095B2 (en) * 2008-08-15 2014-08-26 Georgetown University Na channels, disease, and related assays and compositions
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
US20120107331A1 (en) 2009-05-15 2012-05-03 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
WO2011022502A1 (en) 2009-08-18 2011-02-24 Georgetown University Boronic acid compositions and methods related to cancer
US20110060000A1 (en) 2009-09-10 2011-03-10 Maurizio Grimaldi Acridine analogs in the treatment of gliomas
WO2011088076A2 (en) 2010-01-12 2011-07-21 Yale University Structured rna motifs and compounds and methods for their use
WO2011112670A2 (en) 2010-03-09 2011-09-15 Board Of Regents, University Of Texas System Methods and compositions for chlamydial antigens for diagnosis and treatment of chlamydial infection and disease
JP2013525285A (ja) 2010-04-08 2013-06-20 サンフォード−バーナム メディカル リサーチ インスティテュート 化合物の送達を増強するための方法および組成物
US20130143955A1 (en) 2010-08-09 2013-06-06 Yale University Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
EP2651429B1 (de) 2010-12-15 2018-03-28 Neuroadjuvants, Inc. Neuropeptidanaloga, zusammensetzungen daraus und verfahren zur behandlung von schmerzen damit
US20140303013A1 (en) 2011-03-15 2014-10-09 University Of Utah Research Foundation Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof
WO2012135385A1 (en) 2011-03-28 2012-10-04 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
WO2013036636A1 (en) 2011-09-06 2013-03-14 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
WO2014008475A2 (en) 2012-07-05 2014-01-09 The Ohio State University Compositions and methods related to viral vaccines
WO2014141111A1 (en) 2013-03-14 2014-09-18 Pluristem Ltd. Methods for prevention and treatment of graft-versus-host disease
US9783576B2 (en) 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
WO2015003149A2 (en) 2013-07-05 2015-01-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble cd33 for treating myelodysplastic syndromes (mds)
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
WO2016049380A1 (en) 2014-09-24 2016-03-31 University Of Utah Research Foundation Ebolavirus pre-hairpin intermediate mimics and methods of use
EP3247807B1 (de) 2015-01-20 2020-12-16 Adcure Biotechnologies, LLC. Adenovirusvarianten ohne target und zugehörige verfahren
EP3258961A4 (de) 2015-02-20 2018-08-22 Board of Regents, The University of Texas System Verfahren und zusammensetzungen für abgeschwächte chlamydien als impfstoff und vektor
US10765754B2 (en) 2015-08-28 2020-09-08 Navigen, Inc. Compositions and methods related to inhibition of respiratory syncytial virus entry
CN109069577B (zh) 2016-01-07 2022-08-19 纳维根公司 Hiv进入的d-肽抑制剂以及使用方法
US10751340B2 (en) 2016-06-06 2020-08-25 University Of Central Florida Research Foundation, Inc. Combination therapy to improve brain function or promote neurogenesis for treating neurodegenerative conditions
US20200085890A1 (en) 2016-07-29 2020-03-19 Ohio State Innovation Foundation Expression of pten-long with ocolytic viruses
WO2018067825A1 (en) 2016-10-05 2018-04-12 University Of Central Florida Research Foundation, Inc. Methods and compositions related to nk cell and anti-pdl1 cancer therapies
CA3057680A1 (en) 2017-03-24 2018-09-27 Ohio State Innovation Foundation Novel recombinant adeno-associated viral vectors restricting off-target transduction in liver and uses thereof
RU2019131252A (ru) 2017-03-28 2021-04-28 Огайо Стейт Инновейшн Фаундейшн Пептидные вакцины на основе pd1 человека и их применение
US20230140818A1 (en) 2017-04-27 2023-05-04 The University Of Hong Kong Use of hcn inhibitors for treatment of cancer
JP2020521447A (ja) 2017-05-25 2020-07-27 ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド 天然キラー細胞による殺傷に対する腫瘍細胞の感受性を高めるための新規な腫瘍溶解性ウイルス
WO2019067403A2 (en) 2017-09-26 2019-04-04 Sanford Burnham Prebys Medical Discovery Institute COMPOSITIONS AND METHODS FOR EVALUATION OF PAINFUL DEMYELINIZING AND NON-DEMYELING DISEASES
JP2021521100A (ja) 2018-04-06 2021-08-26 ノース カロライナ ステート ユニバーシティＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 癌免疫療法のためのチェックポイント阻害剤の細胞集団を介した送達
US11717551B2 (en) 2018-05-07 2023-08-08 Georgia State University Research Foundation, Inc. Compositions and methods related to Rhamnus prinoides (GESHO) extract for the inhibition of polymicrobial biofilm formation
WO2020006493A1 (en) 2018-06-29 2020-01-02 North Carolina State University In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
EP3847650A1 (de) 2018-09-06 2021-07-14 The Broad Institute, Inc. Nukleinsäureanordnungen zur gezielten verabreichung
US11331269B2 (en) 2018-09-06 2022-05-17 Massachusetts Institute Of Technology Methods and compositions targeting lung microbiota and its responding immune pathways for lung cancer treatment
US20210388389A1 (en) 2018-10-30 2021-12-16 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
WO2020161686A1 (en) 2019-02-09 2020-08-13 King Abdullah University Of Science And Technology Compositions and methods for cancer diagnosis and prognosis
CA3142777A1 (en) 2019-06-21 2020-12-24 Vaccinex, Inc. Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
US11225508B1 (en) 2020-09-23 2022-01-18 The University Of North Carolina At Chapel Hill Mouse-adapted SARS-CoV-2 viruses and methods of use thereof
AU2021387970A1 (en) 2020-11-27 2023-06-29 General Nanotherapeutics Llc Methods and composition for treatment of immune-mediated diseases
US20230279442A1 (en) 2021-12-15 2023-09-07 Versitech Limited Engineered cas9-nucleases and method of use thereof
WO2023173137A1 (en) 2022-03-11 2023-09-14 Yale University Compositions and methods for efficient and stable genetic modification of eukaryotic cells
WO2023220644A1 (en) 2022-05-10 2023-11-16 Yale University Compositions and methods of synthetic ctla-4 tails for reprogramming of car-t cells and enhancement of anti-tumor efficacy
KR20230167924A (ko) * 2022-06-03 2023-12-12 현대제철 주식회사 전기로
WO2024064824A2 (en) 2022-09-21 2024-03-28 Yale University Compositions and methods for identification of membrane targets for enhancement of nk cell therapy
WO2024102997A1 (en) 2022-11-11 2024-05-16 Peterson Jeff R Gout flare prevention methods using il-1β inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US848422A (en) * 1905-06-23 1907-03-26 Frank Wynne Method of maintaining or increasing the fluidity of molten or semimolten materials by means of electricity.
US1339428A (en) * 1916-03-24 1920-05-11 Ludlum Electric Furnace Corp Method of operating an electric furnace

Also Published As

Publication number Publication date
FR1601438A (de) 1970-08-24
BE739974A (de) 1970-03-16
BR6913348D0 (pt) 1973-01-02
LU59646A1 (de) 1970-01-12
DE1952407A1 (de) 1970-08-20
US3610795A (en) 1971-10-05
JPS4829422B1 (de) 1973-09-10
GB1252310A (de) 1971-11-03
ES372628A1 (es) 1971-11-01
DE1952407B2 (de) 1971-03-11

Similar Documents

Publication Publication Date Title
FR1601438A (de)
AU1946070A (de)
AU2374870A (de)
FR1602675A (de)
AU6168869A (de)
AU6171569A (de)
AU2952567A (de)
AU2581067A (de)
AR203075Q (de)
AU2580267A (de)
BE726730A (de)
BE722485A (de)
AU2496167A (de)
AU3083868A (de)
BE728094A (de)
BE728058A (de)
BE727925A (de)
BE727497A (de)
BE727478A (de)
BE727095A (de)
BE727603A (de)
BE726589A (de)
BE725475A (de)
BE724630A (de)
BE722985A (de)